New pill aims to stop hives flares in their tracks

NCT ID NCT06927999

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times

Summary

This study tests an experimental drug called ARS-2 to see if it can quickly relieve itching and hives during sudden flare-ups in people with chronic spontaneous urticaria (long-term hives). About 42 adults who get moderate to severe hives 1-2 times a month while on daily treatment will take either a low or high dose of ARS-2 or a placebo during separate flare events. The goal is to measure how well the drug reduces itch and hive severity compared to no active treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URTICARIA CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bernstein Clinical Research Center, LLC

    RECRUITING

    Cincinnati, Ohio, 45236, United States

    Contact

  • Endeavor Health Clinical Trials Center

    RECRUITING

    Glenview, Illinois, 60026, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30

    NOT_YET_RECRUITING

    Berlin, 12203, Germany

Conditions

Explore the condition pages connected to this study.